A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose
← catalyst calendarSponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
8actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-21 | actual | When the study began enrolling |
| Primary completion | 2025-05-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-17 | actual | The whole study's end, after follow-up |
| First posted | 2025-03-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pain
Intervention
- Drug: 14C-VX-993
Primary outcomes
what the primary-completion date above is the date OFTerminal Phase Rate Constant (λz) of VX-993 in Plasma
measured From Day 1 up to Day 25
Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-tlast) of VX-993 in Plasma
measured From Day 1 up to Day 25
Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-993 in Plasma
measured From Day 1 up to Day 25
Apparent Clearance (CL/F) of VX-993 in Plasma
measured From Day 1 up to Day 25
Maximum Observed Plasma Concentration (Cmax) of VX-993 in Plasma
measured From Day 1 up to Day 25
Time for VX-993 to Reach Maximum Concentration (Tmax) in Plasma
measured From Day 1 up to Day 25
Apparent Volume of Distribution (Vz/F) (Based on the Terminal Phase) of VX-993 in Plasma
measured From Day 1 up to Day 25
Terminal Phase Rate Constant (λz) of Total Radioactivity (TRA) in Whole blood and Plasma
measured From Day 1 up to Day 25
Amount of Radioactivity Excreted (Ae) of TRA in Urine, Feces and Vomitus (if applicable)
measured Pre dose up to Day 25
AUC0-tlast of TRA in Whole blood and Plasma
measured From Day 1 up to Day 25
AUC0-inf of TRA in Whole blood and Plasma
measured From Day 1 up to Day 25
CL/F of TRA in Whole blood and Plasma
measured From Day 1 up to Day 25
Renal Clearance (CLr) of TRA in Urine and Feces
measured Pre dose up to Day 25
Cmax of TRA in Whole blood and Plasma
measured From Day 1 up to Day 25
Fraction (percent) of Dose Excreted Unchanged in Urine of TRA
measured Pre dose up to Day 25
Tmax of TRA in Whole blood and Plasma
measured From Day 1 up to Day 25
Apparent Volume of Distribution (Based on the Terminal Phase) of TRA in Whole blood and Plasma
measured From Day 1 up to Day 25
Amount of VX-993 and Metabolites, Expressed as a percent of TRA, in Plasma, Urine and Feces
measured From Day 1 up to Day 25
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed